Trial Profile

Safety and efficacy of Peginterferon alfa 2a (pegasys) given once weekly and once monthly in patients with essential thrombocythaemia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 17 Sep 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2a (Primary)
Indications Essential thrombocythaemia
Focus Adverse reactions; Therapeutic Use

Most Recent Events

17 Sep 2014 New trial record
10 Dec 2013 Primary endpoint: Haematological response to Pegasys at 12 months was met

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com